$0.84 EPS Expected for Balchem Co. (NASDAQ:BCPC) This Quarter

Wall Street analysts forecast that Balchem Co. (NASDAQ:BCPC) will post earnings of $0.84 per share for the current quarter, according to Zacks. Two analysts have issued estimates for Balchem’s earnings. Balchem posted earnings per share of $0.77 in the same quarter last year, which would indicate a positive year over year growth rate of 9.1%. The business is expected to report its next quarterly earnings report on Thursday, February 27th.

On average, analysts expect that Balchem will report full year earnings of $3.16 per share for the current financial year. For the next financial year, analysts expect that the company will report earnings of $3.17 per share, with EPS estimates ranging from $3.07 to $3.27. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Balchem.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings data on Tuesday, November 5th. The basic materials company reported $0.81 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. Balchem had a return on equity of 14.01% and a net margin of 12.43%. The company had revenue of $158.60 million for the quarter, compared to analysts’ expectations of $166.42 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. The firm’s quarterly revenue was up 2.3% on a year-over-year basis.

Several equities analysts recently commented on BCPC shares. HC Wainwright reissued a “positive” rating and set a $110.00 price target (up from $95.00) on shares of Balchem in a research report on Wednesday, November 6th. ValuEngine downgraded shares of Balchem from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub lowered shares of Balchem from a “hold” rating to a “sell” rating in a research note on Thursday, November 21st. Finally, Zacks Investment Research cut shares of Balchem from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $107.67.

Institutional investors have recently made changes to their positions in the company. CWM LLC bought a new stake in Balchem in the second quarter valued at about $31,000. Krane Funds Advisors LLC bought a new stake in Balchem during the second quarter valued at $60,000. Tower Research Capital LLC TRC bought a new stake in Balchem during the second quarter valued at $65,000. First Mercantile Trust Co. acquired a new stake in shares of Balchem during the third quarter worth $72,000. Finally, HM Payson & Co. acquired a new stake in shares of Balchem during the second quarter worth $147,000. Institutional investors own 88.01% of the company’s stock.

Shares of NASDAQ:BCPC traded up $2.44 during mid-day trading on Thursday, hitting $101.40. 111,185 shares of the company traded hands, compared to its average volume of 113,276. The firm has a market cap of $3.26 billion, a P/E ratio of 33.69 and a beta of 1.18. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.31 and a current ratio of 3.33. Balchem has a 52-week low of $73.16 and a 52-week high of $106.56. The firm’s 50 day simple moving average is $100.98 and its 200 day simple moving average is $97.08.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Further Reading: Sell-Side Analysts

Get a free copy of the Zacks research report on Balchem (BCPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.